Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.

Both companies involved in the transaction are based in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.

Novartis is a pharmaceutical company based in Switzerland, while AAA is a French radiopharmaceutical company.

Neos Therapeutics, Inc. (formerly Neostx Inc.) has rejected PDL BioPharma’s plans to acquire its entire outstanding shares for $10.25 a share.

“Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.”

Both pharmaceutical companies involved in the transaction are based in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alembic Pharmaceuticals has acquired generic drug developer Orit Laboratories.

The acquisition enables the Indian pharmaceutical company to expand its footprint in the US.

US-based biotechnology company Amgen plans to acquire the remaining 50% stake in Kirin-Amgen, a joint venture (JV) between integrated beverage company Kirin Holdings and Amgen.

The JV will pay $780m to Kirin and consequently become a wholly owned subsidiary of Amgen.